aTYR PHARMA INC — Form 8-K
Filed October 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 18/100
What the filing says
aTYR Pharma filed an 8-K on October 16, 2026, disclosing submission of matters to a vote of security holders under Item 5.07. The filing provides no detail on what specific matters were submitted, vote counts, percentages, dates, or outcomes—only that a submission occurred. Without substantive disclosure, the business impact cannot be assessed.
Why this rating
Bare procedural disclosure with zero material detail. No specifics on proposal, voting results, or business consequence disclosed. Routine SEC filing housekeeping.
Extracted items
See more from October 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.